Antigen-specific Cancer Immunotherapy (TG01) and Gemcitabine as Adjuvant Therapy in Resected Pancreatic Cancer

Targovax

Status and phase: Completed; Phase 2; Phase 1

Conditions: Pancreatic Cancer, Resected

Treatments: Biological: TG01

Study type: Interventional

Funder types: Industry

Identifiers

NCT02261714

CT TG01-01

Details and patient eligibility

About

The purpose of this study is to investigate the effect of TG01 and Granulocyte macrophage colony stimulating factor (GM-CSF) when given in addition to gemcitabine (chemotherapy) and

• Understand any possible side effects of the additional use of TG01/GM-CSF with gemcitabine
• Investigate whether TG01/GM-CSF when given with gemcitabine can produce an immune response
• Investigate if the treatment can delay or reduce recurrence of the disease

Enrollment: 32 patients

Sex: All

Ages: 18 to 99 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Histologically or cytologically confirmed diagnosis of adenocarcinoma of the pancreas

2. Stage I or II disease (clinical stage T1-3, N0-1, M0 by AJCC staging criteria).

3. Successful surgical resection

   • Complete resection (R0) or with microscopic residual disease (R1)
   • Expected to receive gemcitabine monotherapy as adjuvant chemotherapy

4. Laboratory Values:

   • Absolute neutrophil count ≥ 1.5 x 10^9/l
   • Platelets ≥100 x 10^9/l
   • Haemoglobin ≥ 9 g/dl
   • Total bilirubin ≤ 1.5 x UNL
   • Serum creatinine ≤ 1.5 x UNL
   • Albumin ≥ 2.5 g/dl
   • AST or ALT ≥ 5 x UNL

5. 18 years of age or older.

6. ECOG performance status (PS) of 0-1.

7. Life expectancy of at least 6 months

8. Men and women of childbearing potential must be willing to use effective methods of contraception to prevent pregnancy

9. Provide written (signed) informed consent to participate in the trial prior to any trial specific screening procedures

Exclusion criteria

1. Has received an investigational drug within 4 weeks prior to Trial drug administration

2. Has received previous therapy for pancreatic cancer including radiation or chemotherapy (except for the primary resection or primary neoadjuvant chemotherapy).

3. Is currently receiving any agent with a known effect on the immune system, unless at dose levels that are not immunosuppressive (e.g. Prednisone at 10 mg/day or less or as inhaled steroid at doses used for the treatment of asthma).

4. Has any other serious illnesses or medical conditions such as, but not limited to:

   • Any uncontrolled infection
   • Uncontrolled cardiac failure classification III or IV (NY Heart Association)
   • Uncontrolled systemic and gastro-intestinal inflammatory conditions
   • Bone marrow dysplasia
   • History of auto-immune disease
   • History of adverse reactions to vaccines

5. Known history of positive tests for HIV/AIDS, hepatitis B or C

6. Pregnant or lactating females or have no pregnancy test at baseline (postmenopausal women must have been amenorrhoeic for at least 12 months to be considered of non-childbearing potential).

7. Contraindication to gemcitabine treatment

8. Have had any other malignancies within last 3 years (except for adequately treated carcinoma of the cervix or basal or squamous cell skin cancer)

9. Known malignant brain lesion(s)

10. Are unlikely to start chemotherapy within 12 weeks of surgery (e.g. delayed wound healing, or infection, etc.)

11. Are not expected to complete 6 cycles of chemotherapy

12. Are planned to receive yellow fever or other live (attenuated) vaccines during the course of study

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

32 participants in 1 patient group

TG01/GM-CSF and Gemcitabine

Experimental group

Treatment:

Biological: TG01

Biological: TG01